vs
Side-by-side financial comparison of CALLAN JMB INC. (CJMB) and PAVmed Inc. (PAVM). Click either name above to swap in a different company.
CALLAN JMB INC. is the larger business by last-quarter revenue ($1.2M vs $996.0K, roughly 1.2× PAVmed Inc.). PAVmed Inc. runs the higher net margin — 6465.8% vs -223.8%, a 6689.5% gap on every dollar of revenue.
PAVmed Inc. is a commercial-stage medical technology company that designs, develops and commercializes innovative diagnostic and therapeutic medical products. Its portfolio covers point-of-care diagnostics, interventional oncology and gastroenterology solutions, primarily serving healthcare providers and patients across the United States.
CJMB vs PAVM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $996.0K |
| Net Profit | $-2.6M | $64.4M |
| Gross Margin | 30.3% | -38.7% |
| Operating Margin | -216.6% | -1162.4% |
| Net Margin | -223.8% | 6465.8% |
| Revenue YoY | — | 25.9% |
| Net Profit YoY | — | 464.4% |
| EPS (diluted) | $-0.58 | $1.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.4M | — | ||
| Q2 25 | $1.7M | — | ||
| Q1 25 | $1.4M | — | ||
| Q3 24 | — | $996.0K | ||
| Q2 24 | — | $979.0K | ||
| Q1 24 | — | $1.0M | ||
| Q4 23 | — | $1.0M |
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-2.7M | — | ||
| Q2 25 | $-1.4M | — | ||
| Q1 25 | $-1.2M | — | ||
| Q3 24 | — | $64.4M | ||
| Q2 24 | — | $-10.8M | ||
| Q1 24 | — | $-15.2M | ||
| Q4 23 | — | $-14.0M |
| Q4 25 | 30.3% | — | ||
| Q3 25 | 34.1% | — | ||
| Q2 25 | 38.6% | — | ||
| Q1 25 | 42.5% | — | ||
| Q3 24 | — | -38.7% | ||
| Q2 24 | — | -70.2% | ||
| Q1 24 | — | -72.7% | ||
| Q4 23 | — | -53.5% |
| Q4 25 | -216.6% | — | ||
| Q3 25 | -129.9% | — | ||
| Q2 25 | -84.2% | — | ||
| Q1 25 | -85.4% | — | ||
| Q3 24 | — | -1162.4% | ||
| Q2 24 | — | -1397.8% | ||
| Q1 24 | — | -1389.7% | ||
| Q4 23 | — | -1561.7% |
| Q4 25 | -223.8% | — | ||
| Q3 25 | -188.8% | — | ||
| Q2 25 | -83.9% | — | ||
| Q1 25 | -85.6% | — | ||
| Q3 24 | — | 6465.8% | ||
| Q2 24 | — | -1105.9% | ||
| Q1 24 | — | -1506.1% | ||
| Q4 23 | — | -1338.0% |
| Q4 25 | $-0.58 | — | ||
| Q3 25 | $-0.61 | — | ||
| Q2 25 | $-0.31 | — | ||
| Q1 25 | $-0.32 | — | ||
| Q3 24 | — | $1.44 | ||
| Q2 24 | — | $-1.19 | ||
| Q1 24 | — | $-2.62 | ||
| Q4 23 | — | $-1.90 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $765.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3M | $-4.9M |
| Total Assets | $5.8M | $30.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | — | ||
| Q3 25 | $2.8M | — | ||
| Q2 25 | $4.2M | — | ||
| Q1 25 | $5.2M | — | ||
| Q3 24 | — | $765.0K | ||
| Q2 24 | — | $25.5M | ||
| Q1 24 | — | $25.5M | ||
| Q4 23 | — | $19.6M |
| Q4 25 | $2.3M | — | ||
| Q3 25 | $4.2M | — | ||
| Q2 25 | $5.8M | — | ||
| Q1 25 | $6.8M | — | ||
| Q3 24 | — | $-4.9M | ||
| Q2 24 | — | $-73.9M | ||
| Q1 24 | — | $-68.8M | ||
| Q4 23 | — | $-53.8M |
| Q4 25 | $5.8M | — | ||
| Q3 25 | $7.7M | — | ||
| Q2 25 | $9.0M | — | ||
| Q1 25 | $8.5M | — | ||
| Q3 24 | — | $30.6M | ||
| Q2 24 | — | $39.4M | ||
| Q1 24 | — | $37.3M | ||
| Q4 23 | — | $33.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-659.0K | $-8.9M |
| Free Cash FlowOCF − Capex | — | $-8.9M |
| FCF MarginFCF / Revenue | — | -892.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | -0.14× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-45.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-659.0K | — | ||
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $-563.3K | — | ||
| Q1 25 | $-1.6M | — | ||
| Q3 24 | — | $-8.9M | ||
| Q2 24 | — | $-11.7M | ||
| Q1 24 | — | $-13.1M | ||
| Q4 23 | — | $-11.9M |
| Q4 25 | — | — | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | $-995.8K | — | ||
| Q1 25 | $-1.6M | — | ||
| Q3 24 | — | $-8.9M | ||
| Q2 24 | — | $-11.7M | ||
| Q1 24 | — | $-13.2M | ||
| Q4 23 | — | $-12.1M |
| Q4 25 | — | — | ||
| Q3 25 | -133.5% | — | ||
| Q2 25 | -59.8% | — | ||
| Q1 25 | -108.8% | — | ||
| Q3 24 | — | -892.5% | ||
| Q2 24 | — | -1190.9% | ||
| Q1 24 | — | -1302.1% | ||
| Q4 23 | — | -1149.4% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 26.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 4.2% | ||
| Q4 23 | — | 17.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | -0.14× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CJMB
| Governmental | $1.1M | 91% |
| Other | $106.5K | 9% |
PAVM
Segment breakdown not available.
